← Eichor
Study identifier: NCT07172035 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis

Condition: Cirrhosis · Decompensation · Transjugular Intrahepatic Portosystemic Shunt (TIPS)  ·  Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

PhaseN/A
Planned participants250
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

The traditional view holds that the natural course of cirrhosis is a unidirectional process, characterized by irreversible progression from the compensated stage to the decompensated stage, and is highly likely to develop further decompensation events or even death. However, a growing body of evidence suggests that the natural course of cirrhosis is not always unidirectional - after the removal of the etiology, the structural and functional changes of the liver may be partially reversed. This understanding has given rise to the concept of "liver recompensation," which has been standardized at the Baveno VII Consensus Conference. Notably, in a cohort of patients with alcohol-related cirrhosis, 18% achieved recompensation, which was significantly associated with a reduction of more than 90% in liver-related mortality. In patients with hepatitis B-related cirrhosis, 6% achieved recompensation after treatment with nucleos(t)ide analogs, with a similar improvement in mortality. Transjugular intrahepatic portosystemic shunt (TIPS) is a well-established therapy for complications related to portal hypertension, including gastroesophageal variceal bleeding, refractory ascites, and hepatic hydrothorax. Compared with standard treatment, TIPS has been proven to reduce the incidence of further decompensation and improve transplant-free survival. However, due to portal blood shunting, the risks of abnormal liver function and hepatic encephalopathy (HE) also increase. It is worth noting th…

This description comes directly from the study's public registry record.

Talk to the study team

Yaowei Bai  ·  +8618627162379  ·  baiyaowei918@163.com

Always discuss trial participation with your own doctor first.

Locations (15)

Second Xiangya Hospital, Central South UniversityChangsha, ChinaRecruiting
The Third Xiangya Hospital of Central South UniversityChangsha, ChinaRecruiting
Fujian Medical University Union HospitalFuzhou, ChinaRecruiting
Huanggang Central HospitalHuanggang, ChinaRecruiting
Jingzhou Central HospitalJingzhou, ChinaRecruiting
Jiangxi Provincial People's HospitalNanchang, ChinaRecruiting
The First Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaRecruiting
Shengjing Hospital of China Medical UniversityShenyang, ChinaRecruiting
Shanxi Provincial People's HospitalTaiyuan, ChinaRecruiting
Renmin Hospital of Wuhan UniversityWuhan, ChinaRecruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaRecruiting
Zhongnan Hospital of Wuhan UniversityWuhan, ChinaRecruiting

+ 3 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07172035